GB2367011A — Metered dose inhaler for salmeterol
Assigned to Glaxo Group Ltd · Expires 2002-03-27 · 24y expired
What this patent protects
A metered dose inhaler possessing a canister containing salmeterol (or a physiologically acceptable salt thereof) and a hydrofluoroalkane propellant, a dose metering valve, and an actuator, the actuator body possessing a nozzle block for receiving the dose metering valve and defi…
USPTO Abstract
A metered dose inhaler possessing a canister containing salmeterol (or a physiologically acceptable salt thereof) and a hydrofluoroalkane propellant, a dose metering valve, and an actuator, the actuator body possessing a nozzle block for receiving the dose metering valve and defining an exit channel whose diameter at its narrowest point is between 0.2 and 0.4mm and whose length is between 1 and 2mm and/or the ration of the diameter of the exit channel at its narrowest point to its length is between 3.5:1 and 10:1. The drug suspension may contain fluticasone propionate. The dose metering valve possesses a chamber of volume between 20-100žl The exit channel may have a variable diameter along its length be tapered or possess a constriction and connects to an exit chamber at a 50-90{ angle. The inhaler is intended to optimize the fine particle mass (FPM) of the dose.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.